Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

Abstract

Background: There is increasing concern that persistent infection of SARS-CoV-2 within immunocompromised hosts could serve as a reservoir for mutation accumulation and subsequent emergence of novel strains with the potential to evade immune responses.

Methods: We describe three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 by real-time polymerase chain reaction. Viral viability from longitudinally-collected specimens was assessed. Whole-genome sequencing and serological studies were performed to measure viral evolution and evidence of immune escape.

Findings: We found compelling evidence of ongoing replication and infectivity for up to 162 days from initial positive by subgenomic RNA, single-stranded RNA, and viral culture analysis. Our results reveal a broad spectrum of infectivity, host immune responses, and accumulation of mutations, some with the potential for immune escape.

Interpretation: Our results highlight the potential need to reassess infection control precautions in the management and care of immunocompromised patients. Routine surveillance of mutations and evaluation of their potential impact on viral transmission and immune escape should be considered.

Keywords: SARS-CoV-2; case report; immunocompromised; pediatric; persistent infection; variants.

Conflict of interest statement

Declaration of Competing Interests S.D.B. has consulted for Regeneron, Sanofi, and Novartis on topics unrelated to this study. S.D.B., and K.R. have filed provisional patent applications related to serological tests for SARS-CoV-2 antibodies. All other authors have no competing interests.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1

Clinical timeline. Timelines of symptoms, hospital admissions, and treatment for patient 1, patient 2, and patient 3 are labelled by date from initial positive RT-PCR (day 0). Colored bars indicate time periods where patients were symptomatic, required supplementary oxygen, or received treatment (Remdesivir or convalescent plasma). The phases of chemotherapy are also shown. ED, emergency department; LD-chemo, lymphodepleting-chemotherapy.

Fig. 2

SARS-CoV-2 Viral load by method. Time course of viral load by routine, negative-strand, and subgenomic RT-PCR from nasopharyngeal or combined nares/oropharyngeal swabs collected from each patient. Viral culture results are indicated in pink. Corresponding serum anti-SARS-CoV-2 IgG values are plotted in blue. For patient 2, IgG was measured before and after administration of convalescent plasma at the indicated timepoints.

Fig. 3

Anti-SARS-CoV-2 antibody responses. Serum samples from two immunocompromised children (a, c) and one young adult (b) were collected up to 176 days after initial positive SARS-CoV-2 PCR test. Plasma samples from four non-immunocompromised COVID-19 patients were analyzed for comparison (d). Antibodies specific for SARS-CoV-2 Spike RBD (top row), S1 subunit (second row), and N protein (third row) were measured. RBD-ACE2 blocking activity was assessed in a competition ELISA and is shown as percentage of blocking (e). The cutoff for seropositivity was defined as the mean absorbance + 3 SD of 94 historical negative serum samples in each assay. Color coding for isotypes: IgG (blue), IgM (green), IgA (red). Dotted lines depict the cutoff for seroconversion for the different isotypes in each assay. Individual donors were shown with different symbols (d). * indicates timepoints of convalescent plasma infusion in patient 2. Values are means ± 1 standard deviation for experimental triplicates.

Fig. 4

Accumulation of SARS-CoV-2 variants. Each row represents viral culture, strand-specific RT-PCR (ssRT-PCR), subgenomic RT-PCR (sgRT-PCR) and sequencing from longitudinally derived specimens numbered by days from initial positive test (day 0). Boxes represent distinct variants, and shading reflects variant allele frequency (cutoff = 0.25). Corresponding genes are labeled in top row and colored to represent variant annotation (see legend). UTR, untranslated region; S, spike; E, envelope; M, matrix; N, nucleocapsid.